MedPath

A Study Comparing Megestrol Acetate at 800 mg/Day, and Placebo in AIDS Patients With Anorexia and Cachexia

Phase 3
Completed
Conditions
Cachexia
HIV Infections
Anorexia
Registration Number
NCT00002067
Lead Sponsor
Bristol-Myers Squibb
Brief Summary

To compare the effects of megestrol acetate and placebo on body weight, anorexia, cachexia, calorie intake, and nutritional parameters of patients with a confirmed diagnosis of AIDS. To determine whether megestrol acetate relative to placebo improves the perception of well-being among AIDS patients with cachexia. To evaluate megestrol acetate's effect on immune function via skin test reactivity, T4/T8 ratio, and total lymphocytes.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (14)

Dr Mark Goldstein

🇺🇸

Los Angeles, California, United States

Summitt Med Ctr / San Francisco Gen Hosp

🇺🇸

Oakland, California, United States

Palo Alto Veterans Adm Med Ctr / Stanford Univ

🇺🇸

Palo Alto, California, United States

Eisenhower Med Ctr

🇺🇸

Rancho Mirage, California, United States

UCD Med Ctr

🇺🇸

Sacramento, California, United States

San Francisco AIDS Clinic / San Francisco Gen Hosp

🇺🇸

San Francisco, California, United States

San Francisco Veterans Administration Med Ctr

🇺🇸

San Francisco, California, United States

Denver Public Health Dept

🇺🇸

Denver, Colorado, United States

Miami Veterans Administration Med Ctr

🇺🇸

Miami, Florida, United States

Univ of South Florida

🇺🇸

Tampa, Florida, United States

Scroll for more (4 remaining)
Dr Mark Goldstein
🇺🇸Los Angeles, California, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.